ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

DMAC Company Profile and Key Details

NASDAQ : DMAC

DiaMedica Therapeutics Inc.

$3.51

-0.03-0.85%

At Close 4:00 PM

66.37

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

DiaMedica Therapeutics Inc. (DMAC) stock declined over -1.14%, trading at $3.47 on NASDAQ, down from the previous close of $3.51. The stock opened at $3.50, fluctuating between $3.31 and $3.55 in the recent session.

Stock Snapshot

3.51

Prev. Close

3.5

Open

148.71M

Market Cap

42.86M

Number of Shares

3.305

Day Low

3.545

Day High

-5.78

P/E Ratio

56.13%

Free Float in %

-0.6

EPS (TTM)

1.35

Book Value

-0.49

Cash Flow per Share

84.32K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 15, 2025	3.53	3.88	3.49	3.51	62.34K
Apr 14, 2025	3.55	3.73	3.50	3.54	60.18K
Apr 11, 2025	3.52	3.60	3.45	3.47	50.75K
Apr 10, 2025	3.64	3.82	3.40	3.51	58.48K
Apr 09, 2025	3.35	3.75	3.26	3.70	81.84K
Apr 08, 2025	3.59	3.64	3.30	3.38	77.83K
Apr 07, 2025	3.40	3.57	3.19	3.48	114.4K
Apr 04, 2025	3.57	3.67	3.32	3.50	117.36K
Apr 03, 2025	3.85	3.86	3.51	3.68	85.7K
Apr 02, 2025	3.70	4.23	3.70	3.96	130.05K
Apr 01, 2025	3.76	3.94	3.47	3.75	128.42K
Mar 31, 2025	3.75	3.84	3.62	3.79	92.36K
Mar 28, 2025	4.13	4.24	3.76	3.82	160.05K
Mar 27, 2025	4.24	4.53	4.12	4.14	83.2K
Mar 26, 2025	4.58	4.58	4.08	4.08	221.27K
Mar 25, 2025	4.95	5.03	4.52	4.57	140.6K
Mar 24, 2025	5.04	5.12	4.90	4.95	50.1K
Mar 21, 2025	5.05	5.10	4.90	4.98	74.72K
Mar 20, 2025	5.26	5.47	5.05	5.14	75.42K
Mar 19, 2025	5.25	5.34	5.11	5.24	120.11K

Contact Details

Minneapolis, MN 55447

United States

Website: https://www.diamedica.comContact: 763 612 6755

About Company

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Frequently Asked Questions

What is the current DiaMedica Therapeutics Inc. (DMAC) stock price?

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) stock price is $3.47 in the last trading session. During the trading session, DMAC stock reached the peak price of $3.55 while $3.31 was the lowest point it dropped to. The percentage change in DMAC stock occurred in the recent session was -1.14% while the dollar amount for the price change in DMAC stock was -$0.04.

DMAC's industry and sector of operation?

The NASDAQ listed DMAC is part of Biotechnology industry that operates in the broader Healthcare sector. DiaMedica Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of DMAC?

Mr. Dietrich John Pauls MBA
Pres, Chief Executive Officer & Director
Dr. Kirsten L. Gruis M.D., M.S.
Chief Medical Officer
Mr. Dominic R. Cundari
Chief Commercial Officer
Mr. Scott B. Kellen C.A.
Chief Financial Officer & Company Sec.
Dr. Edward G. Calamai Ph.D.
Consulting Head of Manufacturing
Ms. Julie VanOrsdel Daves CCRP
Senior Vice President of Clinical Devel. Operations
Mr. David J. Wambeke
Chief Bus. Officer
Ms. Maria Carolina Petrini
Chief Commercial Officer

How DMAC did perform over past 52-week?

DMAC's closing price is 64.02% higher than its 52-week low of $2.14 where as its distance from 52-week high of $6.82 is -48.52%.

How many employees does DMAC have?

Number of DMAC employees currently stands at 27.

Link for DMAC official website?

Official Website of DMAC is: https://www.diamedica.com

How do I contact DMAC?

DMAC could be contacted at phone 763 612 6755 and can also be accessed through its website. DMAC operates from Two Carlson Parkway, Minneapolis, MN 55447, United States.

How many shares of DMAC are traded daily?

DMAC stock volume for the day was 84.32K shares. The average number of DMAC shares traded daily for last 3 months was 89.66K.

What is the market cap of DMAC currently?

The market value of DMAC currently stands at $148.71M with its latest stock price at $3.47 and 42.86M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

News

Investing Crypto Market Business US Stocks

Useful Links

Screener Market Data Insider Transactions Upgrades & Downgrades 52 Week Highs & Lows Unusual Volume Dividend Calendar Earnings Calendar

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	27
Beta	1.49
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology